SCHEMBL6020364

SCHEMBL6020364

CC(C)COC(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NCC#N

nearest known ligand 0.77

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ NMBR P28336 12/20 0.77
▸ TACR1 P25103 1/20 0.77
▸ CTSL P07711 2/20 0.74
▸ CTSS P25774 1/20 0.74
▸ CTSK P43235 1/20 0.74
▸ MAPT P10636 3/20 0.69
▸ SMN1; SMN2 Q16637 1/20 0.69
▸ GAA P10253 1/20 0.60
▸ HTT P42858 1/20 0.60
▸ TACR3 P29371 1/20 0.60
▸ LMNA P02545 1/20 0.58
▸ ECE1 P42892 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6020879 0.92 NMBR (0.79) NMBRTACR1CTSLCTSSCTSK
SCHEMBL6020968 0.90 CTSL (0.77) NMBRTACR1CTSLCTSSCTSK
SCHEMBL6019706 0.90 CTSL (0.77) NMBRTACR1CTSLCTSSCTSK
SCHEMBL6019220 0.89 CTSL (0.81) NMBRTACR1CTSLCTSSCTSK
SCHEMBL6020884 0.88 NMBR (0.71) NMBRTACR1CTSLCTSSCTSK
SCHEMBL6020423 0.87 CTSL (0.69) NMBRTACR1CTSLCTSSCTSK
SCHEMBL6020516 0.87 CTSL (0.72) NMBRTACR1CTSLCTSSCTSK
SCHEMBL19359093 0.87 NMBR (0.74) NMBRTACR1MAPTSMN1; SMN2ECE1
SCHEMBL5189162 0.87 NMBR (0.74) NMBRTACR1MAPTSMN1; SMN2ECE1
SCHEMBL2228491 0.87 NMBR (0.74) NMBRTACR1MAPTSMN1; SMN2ECE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060252813-A1 Apparatus for curing a composite laminate JERINI AG (DE) 2006-11-09 — — US claimed
EP-1575903-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES Jerini AG (DE) 2005-09-21 — — EP claimed
WO-2004065353-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES JERINI AG (DE) 2004-08-05 — — WO claimed
WO-2004056755-A2 COMPOUNDS FOR THE INHIBITION OF NON-PROTEOLYTIC ENZYMES JERENI AG (DE) 2004-07-08 — — WO claimed
EP-1433778-A1 Use of nitriles as rotamase inhibitors Jerini AG (DE) 2004-06-30 — — EP claimed
EP-1433779-A1 Use of nitriles as inhibitors of non-proteolytic enzymes Jerini AG (DE) 2004-06-30 — — EP claimed
US-20060252813-A1 Apparatus for curing a composite laminate JERINI AG (DE) 2006-11-09 — — US disclosed
EP-1575903-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES Jerini AG (DE) 2005-09-21 — — EP disclosed
WO-2004065353-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES JERINI AG (DE) 2004-08-05 — — WO disclosed
WO-2004056755-A2 COMPOUNDS FOR THE INHIBITION OF NON-PROTEOLYTIC ENZYMES JERENI AG (DE) 2004-07-08 — — WO disclosed
EP-1433778-A1 Use of nitriles as rotamase inhibitors Jerini AG (DE) 2004-06-30 — — EP disclosed
EP-1433779-A1 Use of nitriles as inhibitors of non-proteolytic enzymes Jerini AG (DE) 2004-06-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252813-A1 Apparatus for curing a composite laminate DHX29, HDHD5, DHRS9 NMBR 2003/4885TACR1 3501/4885CTSL 2274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback